In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target specific ligands to receptors on cancer cells, but it may offer the convenience of oral rather than parenteral delivery. Using targeted systems to deliver oligonucleotides, Nuvec® shows great promise as a tactic for the treatment of many diseases, including cancer. By using a more targeted approach, the drawbacks of conventional chemotherapy treatment, such as undesirable side effects, can be avoided.  

Read the article published in Manufacturing Chemist here.